JOHN H. LAWRENCE, M.D.; LOUIS R. WASSERMAN, M.D., F.A.C.P.
The treatment of multiple myeloma has always been discouraging. As in other inoperable malignant conditions, x-ray therapy has been used wherever indicated, and the use of stilbamidine by Snapper has been successful in relieving pain due to myeloma, but no prolongation of life has been apparent.1 Urethane has recently been used in the treatment of multiple myeloma by Loge and Rundles.2 Subsidence of pain and a decrease of abnormal cells occurred in some cases. In a series of 83 patients studied by Bayrd and Heck, the average length of life in multiple myeloma was 19 months, and the duration seemed
Learn more about subscription options.
Register Now for a free account.
LAWRENCE JH, WASSERMAN LR. MULTIPLE MYELOMA: A STUDY OF 24 PATIENTS TREATED WITH RADIOACTIVE ISOTOPES (P32 AND SR88)(MULTIPLE MYELOMA: A STUDY OF 24 PATIENTS TREATED WITH RADIOACTIVE ISOTOPES (P32 AND SR88)*). Ann Intern Med. 1950;33:41–55. doi: 10.7326/0003-4819-33-1-41
Download citation file:
Published: Ann Intern Med. 1950;33(1):41-55.
Hematology/Oncology, Multiple Myeloma.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only